Issue |
Med Sci (Paris)
Volume 30, Number 10, Octobre 2014
|
|
---|---|---|
Page(s) | 896 - 901 | |
Section | M/S Revues | |
DOI | https://doi.org/10.1051/medsci/20143010017 | |
Published online | 14 October 2014 |
L’excrétion trans-intestinale de cholestérol (TICE)
Une nouvelle voie d’épuration du cholestérol plasmatique
Trans-intestinal cholesterol excretion (TICE): a new route for cholesterol excretion
IRS-UN, institut du thorax, unité Inserm UMR 1087/CNRS UMR 6291, 8, quai Moncousu, 44007
Nantes Cedex 1, France
L’intestin joue un rôle crucial dans l’absorption et la sécrétion lymphatique du cholestérol sous forme de chylomicrons. La découverte de l’excrétion trans-intestinale de cholestérol (TICE) renforce l’implication de l’intestin dans le métabolisme du cholestérol. Le TICE est inductible, complémentaire de l’excrétion par la voie biliaire, et permet l’élimination directe du cholestérol sanguin dans la lumière intestinale. Cette voie est mal caractérisée, mais plusieurs acteurs moléculaires du TICE ont été récemment identifiés. Deux études montrent que le TICE est impliqué dans la voie du transport inverse du cholestérol, anti-athérogène, suggérant que sa stimulation pourrait contribuer à réduire les maladies cardiovasculaires.
Abstract
The small intestine plays a crucial role in dietary and biliary cholesterol absorption, as well as its lymphatic secretion as chylomicrons (lipoprotein exogenous way). Recently, a new metabolic pathway called TICE (trans-intestinal excretion of cholesterol) that plays a central role in cholesterol metabolism has emerged. TICE is an inducible way, complementary to the hepatobiliary pathway, allowing the elimination of the plasma cholesterol directly into the intestine lumen through the enterocytes. This pathway is poorly characterized but several molecular actors of TICE have been recently identified. Although it is a matter of debate, two independent studies suggest that TICE is involved in the anti-atherogenic reverse cholesterol transport pathway. Thus, TICE is an innovative drug target to reduce cardiovascular diseases.
© 2014 médecine/sciences – Inserm
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.